Investment Rating - The investment rating for the company is "Buy" and it is maintained [9]. Core Insights - The company reported a revenue of 27.88 billion HKD for 2025, representing a year-on-year growth of 0.4%. The attributable net profit was 2.47 billion HKD, which is a 6.6% increase compared to the previous year. The total dividend per share for 2025 was 0.487 HKD, up from 0.40 HKD in 2024, with a payout ratio of 45% compared to 40% in 2024 [2][6]. - The company is a leader in the global monosodium glutamate (MSG) industry, with expectations for industry demand to increase as the major competitors finish their production expansions in 2024. The company is also expanding its overseas operations, particularly in Kazakhstan, which is expected to contribute to its performance starting in 2026 [9]. - The company experienced significant growth in sales volumes for MSG, threonine, and lysine, despite a decline in average selling prices. The sales volume for MSG reached 1.804 million tons, a 10.1% increase year-on-year, while the average price fell by 15.4% to 5,681 HKD per ton. The animal nutrition segment saw a gross profit of 2.5 billion HKD, a 23.0% increase, with threonine and lysine sales volumes growing by 31.1% and 30.4%, respectively [9]. Summary by Relevant Sections Financial Performance - Revenue for 2025 was 27.88 billion HKD, with a net profit of 2.47 billion HKD. The dividend per share increased to 0.487 HKD, with a payout ratio of 45% [2][6]. Business Segments - The food additives segment generated 13.389 billion HKD in revenue, down 6.8%, but the gross margin improved by 2.7 percentage points to 13.5%. The animal nutrition segment's gross profit rose to 2.5 billion HKD, with a gross margin of 23.7% [9]. - The high-end amino acids segment saw a revenue decline of 11.0%, while the colloid segment's revenue decreased by 32.5% [9]. Market Outlook - The company anticipates a recovery in product prices starting in early 2026, following a period of decline. Prices for MSG and amino acids have begun to rise, supported by improved demand and rising raw material costs [9].

Core Viewpoint - Da Cheng Biochemical Technology (00809) expects a significant decline in net income for the fiscal year ending December 31, 2025, projecting between HKD 100 million and HKD 300 million, compared to approximately HKD 746 million for the fiscal year ending December 31, 2024 [1] Financial Performance - The company anticipates revenue and gross profit to increase by approximately 13.9% and 2.8%, respectively, from about HKD 2.001 billion and HKD 191 million in the previous year to approximately HKD 2.279 billion and HKD 196 million in the current year [1] - However, the gross profit margin is expected to decline from 9.5% in the previous year to 8.6% in the current year [1] Factors Affecting Performance - The anticipated decline in gross profit margin and net income is primarily attributed to rising domestic corn prices starting mid-2025, which will increase operational costs for the company [1] - Additionally, the European Union's anti-dumping investigation into mainland China's lysine has led to an oversupply of lysine products in the domestic market, negatively impacting the company's gross profit margin [1] - The company will also not recognize a one-time gain of approximately HKD 1.962 billion following the completion of the sale of eight subsidiaries on December 30, 2024 [1]

Group 1: Overview of the Two Sessions - The growth target has been adjusted downwards from 5% to a range of 4.5-5%, with a continued focus on consumption and domestic demand [2][9] - Fiscal spending is expected to remain close to last year's levels, with a total deficit of 11.9 trillion yuan for 2026, comprising a deficit of 5.89 trillion yuan, special bonds of 4.4 trillion yuan, and special treasury bonds of 1.6 trillion yuan [2][9] - Special treasury bonds of 2.5 billion yuan will be allocated for new consumption, with an additional 1 billion yuan for fiscal-financial collaborative special funds [2][9] Group 2: Performance Trading Period Post Two Sessions - The correlation between market trading signals and performance changes will strengthen after the Two Sessions, with a focus on price increases and overseas expansion [3][13] - The upcoming month will see a concentrated disclosure of annual and quarterly reports, which will significantly influence market trading styles and directions [3][13] - High-prosperity industries are expected to focus on overseas "offensive HALO" and domestic "defensive HALO" strategies [3][15] Group 3: Impact of Rising Oil Prices on Asset Classes and Industries - During the oil price upcycle, stocks and commodities tend to perform well, with a monthly increase probability of 73% for stocks and 68% for commodities [4][26] - In contrast, during the downcycle, gold becomes a focus, with a monthly increase probability of 62% [4][26] - Key cyclical industries during the oil price upcycle include food and beverage, banking, automotive, home appliances, coal, and chemicals, which show significant cyclical characteristics [4][26] Group 4: Investment Strategy Directions - The report recommends focusing on "offensive HALO" strategies, which include price increases and overseas expansion in sectors such as TDI, amino acids, and high-end manufacturing [5] - Defensive HALO strategies involve sectors with low fund holdings, such as coal and construction, as well as TMT sectors with low correlation [5] - Emerging technology sectors like commercial aerospace, domestic computing power, and quantum communication are highlighted as potential catalysts for investment [5]

Core Insights - The 11th Bio-based Conference and Exhibition will be held in Shanghai from May 20-22, focusing on bio-based chemicals and materials, featuring 11 thematic forums, 7 concurrent activities, and 1000 new product displays [2] Group 1: Company Overview - Kasei Biotech, established in 2000, focuses on synthetic biology and bio-manufacturing technology, becoming a global leader in producing new bio-based materials [3] - Kasei Biotech's revenue for 2025 is projected to reach 3.295 billion yuan, marking an 11.41% increase, with a net profit of 566 million yuan, up 15.7% [3] - Huaheng Biotech, founded in 2005, plans to list in Hong Kong and expects a revenue of 2.885 billion yuan in 2025, a 32.5% increase, but a net profit decrease of approximately 30% [9][10] - Huadong Medicine achieved a revenue of 41.906 billion yuan in 2024, a 3.16% increase, with a net profit of 3.512 billion yuan, up 23.72% [14] Group 2: Main Business Composition - Kasei Biotech's main revenue sources include long-chain dicarboxylic acids (2.67 billion yuan, 90.26% of revenue) and bio-based polyamides (144 million yuan, 4.88% of revenue) [6] - Huaheng Biotech's main products include amino acids (1.509 billion yuan, 69.29% of revenue) and vitamins (207 million yuan, 9.49% of revenue) [10] - Huadong Medicine's industrial microbiology segment saw revenue growth from 510 million yuan in 2022 to 711 million yuan in 2024, with a CAGR of 18.07% [14] Group 3: Research and Development Projects - Kasei Biotech is investing in projects like bio-manufacturing research with a total investment of 6.3 million yuan, focusing on fermentation and extraction technology [7] - Huaheng Biotech has multiple ongoing projects, including optimizing amino acid production strains and developing high-purity amino acid removal processes [11][12] - Huadong Medicine has initiated 393 research projects in industrial microbiology, focusing on xRNA raw materials and health-related products [18] Group 4: Development Strategies - Kasei Biotech aims to expand large-scale applications of bio-materials to replace petrochemical products and utilize agricultural waste for bio-manufacturing [8] - Huaheng Biotech focuses on becoming a leader in synthetic biology through innovation and collaboration, emphasizing the use of renewable resources [13] - Huadong Medicine is accelerating its business layout through cooperation and acquisitions, focusing on xRNA raw materials and health products [25] Group 5: Financial Performance - Kasei Biotech's revenue for 2025 is projected to be 3.295 billion yuan, with a net profit of 566 million yuan [3] - Huaheng Biotech expects a revenue of 2.885 billion yuan in 2025, with a significant decrease in net profit [9] - Huadong Medicine's revenue reached 41.906 billion yuan in 2024, with a notable increase in net profit [14] Group 6: Market Trends - The bio-based industry is witnessing a shift towards sustainable materials, with companies focusing on reducing reliance on fossil fuels and enhancing the use of agricultural by-products [8][13] - The demand for bio-based products is expected to grow, driven by environmental concerns and regulatory support for sustainable practices [2][8]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of March 1, 2026 [1] Core Insights - The supply-side variables in the pharmaceutical industry are increasing, leading to an expansion in price adjustments. The raw material drug industry is particularly sensitive to these changes, with the penicillin supply chain already experiencing price rebounds. For instance, the import price limit for 6-APA has been set at approximately 260 RMB/kg, prompting domestic companies to raise their prices [2] - The GLP-1 oral medication era is actively beginning, with Chinese companies continuing to explore international markets. Notably, Eli Lilly's sales of its GLP-1 drug reached 36.5 billion USD in 2025, and the oral version of semaglutide has been launched in the U.S. market, showing strong initial prescription numbers [3] - The small nucleic acid field is witnessing ongoing collaborations and authorizations, with significant mergers and acquisitions occurring in 2026. For example, China National Pharmaceutical Group is acquiring a domestic siRNA innovator for 1.2 billion RMB [4] - The retail pharmaceutical market showed positive trends in Q4 2025, with a retail scale of 58.8 billion RMB, although the annual growth rate remained slightly negative at -0.57% [5] - The report emphasizes the market value of oral autoimmune drugs, highlighting Takeda's new oral TYK2 inhibitor showing promising results in clinical trials for psoriasis [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index underperformed the CSI 300 index by 0.58 percentage points in the last week, ranking 25th among 31 sectors [19] - Over the past month, the pharmaceutical industry index fell by 2.67%, also underperforming the CSI 300 index by 2.77 percentage points, ranking 28th [22] 2. Pharmaceutical Sector Trends and Valuation - The current PE (TTM) for the pharmaceutical industry index is 37.20, which is below the five-year historical average of 30.78 [40] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of biological agents and oral medications, indicating a positive outlook for psoriasis treatment [42] 4. Important Industry Policies and News - Recent policies include the approval of 292 medical device products by the National Medical Products Administration, indicating regulatory support for the industry [44] - Significant news includes Eli Lilly's positive clinical trial results for its drug, which may enhance its market position [46]

Core Viewpoint - The demand for lysine in China is expected to grow significantly, driven by the transformation of livestock and aquaculture industries towards scale and standardization, with a projected demand of 225.39 million tons by 2025, representing an 18.0% year-on-year increase [1][8]. Market Policy - The Chinese government has issued multiple policies to support the development of the amino acid industry, including lysine, creating a favorable policy environment for its growth [4]. Industry Chain - The lysine industry chain includes upstream components such as corn starch and fermentation agents, midstream production and processing, and downstream applications in feed, food processing, pharmaceuticals, and health products [5]. Demand Structure - The feed sector is the primary market for lysine, expected to account for over 90% of demand by 2025, with significant growth in industrial feed production, which reached 158.5 million tons in the first half of 2025, a 7.7% increase year-on-year [7][8]. Development Status - The continuous upgrade of livestock and aquaculture sectors has led to increased demand for standardized feed and precise nutrition, with lysine's application ratio on the rise, contributing to market growth [1][8]. Export Data - In 2025, China's lysine exports are projected to reach 1.0382 million tons, with an export value of approximately $109.5 million, primarily to countries like the USA, India, and Thailand [9]. Competitive Landscape - The market concentration in the lysine industry has increased, with the top five companies (CR5) accounting for 76.8% of production capacity in 2024, led by Meihua Biological Technology Group, which holds a 25.8% market share [11]. Company Analysis - Meihua Biological Technology Group focuses on large-scale production and innovation in amino acids, with a revenue of 18.22 billion yuan in the first nine months of 2025, where feed amino acids contributed 44.97% [12]. - Ningxia Yipin Biological Technology Co., Ltd. has developed a competitive advantage in the industry, offering a range of products including lysine and other amino acids, with a market presence in over 30 provinces and exports to more than 50 countries [12]. Development Trends - The lysine industry is expected to focus on optimizing production processes and improving efficiency through technological advancements, while also expanding into new application areas beyond traditional feed [13][14]. - The industry is likely to see increased concentration and international expansion as stricter environmental regulations push out less efficient players [15]. - A shift towards green and low-carbon production practices is anticipated, aligning with national carbon reduction goals [16].

Market Dynamics - During the Spring Festival, the domestic pig market experienced a rise followed by a decline, with prices dropping below 11 yuan/kg after the holiday [3] - The average price of pigs nationwide briefly rose to 12 yuan/kg before falling to below 11 yuan/kg due to seasonal demand decline and slow recovery in slaughterhouse operations [3] - The price of meat chicken chicks increased slightly post-holiday due to limited supply from breeding farms, with prices reaching 3.50 yuan/chick for large-scale brands [5] - Egg prices fell to 2.8 yuan/jin, with a slight rebound in the price of culling chickens, which was reported at 4.43 yuan/jin [6][7] Soybean and Corn Market - Domestic soybean meal prices remained stable post-holiday, with trading prices between 3070-3270 yuan/ton, while the futures market showed cautious trading [9] - Corn prices in North China saw a slight increase due to replenishment demand, with purchase prices rising to 2310-2400 yuan/ton, up by 10-30 yuan/ton compared to before the holiday [9] Vitamin and Amino Acid Market - Domestic vitamin E manufacturers have been raising prices, with export prices for vitamin E powder reaching 7.5 USD/kg, while domestic prices have rebounded to 58-60 yuan/kg [10] - The domestic market for lysine remains strong, with stable prices as manufacturers focus on fulfilling prior orders [11] Fish Meal Market - The domestic fish meal market remained stable at high prices, with ordinary steam fish meal quoted at 13,700-14,500 yuan/ton and super steam fish meal at 16,700-17,000 yuan/ton [12] Industry Updates - Giant Agricultural Group reported a 61.28% year-on-year increase in sales of commodity pigs in January 2026, selling 404,400 pigs at an average price of 12.71 yuan/kg [14] - China Starch Holdings Limited expects a significant decrease of approximately 64% in pre-tax profit for the fiscal year 2025 due to rising corn prices and oversupply in the lysine market [15][16]

Core Viewpoint - China Starch (03838) experienced a decline of over 5%, with a current price of HKD 0.175 and a trading volume of HKD 2.4476 million [1] Financial Performance - For the fiscal year ending December 31, 2025, the company expects total revenue of approximately RMB 10.058 billion, while the revenue for 2024 is projected to be RMB 11.415 billion [1] - The company anticipates a significant decrease of about 64% in pre-tax profit for the current year, compared to a pre-tax profit of RMB 838 million for the fiscal year ending December 31, 2024 [1] Factors Affecting Performance - The expected decline in revenue and pre-tax profit is primarily attributed to the rising costs of corn kernels, which negatively impact profit margins [1] - The sharp decline in lysine market prices in the second half of last year has adversely affected profitability [1] - The anticipated traditional peak season for starch sugar did not materialize as expected, further impacting financial performance [1]

Core Viewpoint - China Starch (03838) experienced a decline of over 5%, with a current price of HKD 0.175 and a trading volume of HKD 2.4476 million [1] Financial Performance - For the fiscal year ending December 31, 2025, the company expects total revenue of approximately RMB 10.058 billion, while the revenue for 2024 is projected to be RMB 11.415 billion [1] - The company anticipates a significant decrease of about 64% in pre-tax profit for the current year, compared to a pre-tax profit of RMB 838 million for the fiscal year ending December 31, 2024 [1] Factors Affecting Performance - The primary reasons for the expected decline in revenue and pre-tax profit include rising costs of corn kernels negatively impacting profit margins, a significant drop in lysine market prices in the second half of last year affecting profitability, and the anticipated traditional peak season for starch sugar not materializing as expected [1]

Core Viewpoint - China Starch (03838) experienced a decline of over 5%, with a current price of HKD 0.175 and a trading volume of HKD 2.4476 million [1] Financial Performance - For the fiscal year ending December 31, 2025, the company expects total revenue of approximately RMB 10.058 billion, while the revenue for 2024 is projected to be RMB 11.415 billion [1] - The company anticipates a significant decrease of about 64% in pre-tax profit for the current year, compared to a pre-tax profit of RMB 838 million for the fiscal year ending December 31, 2024 [1] Factors Affecting Performance - The primary reasons for the expected decline in revenue and pre-tax profit include rising costs of corn kernels negatively impacting profit margins, a significant drop in lysine market prices in the second half of the previous year affecting profitability, and the anticipated traditional peak season for starch sugar not materializing as expected [1]